Kevin Harrington, PhD, MBBS, of the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust discusses KEYNOTE-048: progression after the next line of therapy following pembrolizumab or P plus chemotherapy vs EXTREME as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Read here: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.6505
Advertisement